Using TNF receptors to reduce inflammation and promote bone healing in type 1 diabetes
Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes
['FUNDING_R01'] · YALE UNIVERSITY · NIH-10886049
This study is looking at how a special protein can help reduce inflammation and improve bone healing for people with type 1 diabetes, so if you have diabetes and are dealing with bone issues, this research might offer you new treatment options to help your recovery.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10886049 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting TNF receptors can help reduce inflammation and enhance bone regeneration in patients with type 1 diabetes. The study focuses on a protein called progranulin, which has shown promise in promoting healing by interacting with specific receptors involved in bone formation. By exploring the effects of engineered proteins like Atsttrin, the research aims to find new treatments that can improve fracture healing in diabetic patients. Patients participating in this research may receive innovative therapies designed to address the unique challenges posed by diabetes-related bone issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes who experience delayed fracture healing.
Not a fit: Patients without type 1 diabetes or those not experiencing issues with bone healing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve bone healing in patients with type 1 diabetes.
How similar studies have performed: Previous research has shown promise in targeting TNF receptors for treating autoimmune conditions, suggesting potential success for this novel approach.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, CHUANJU — YALE UNIVERSITY
- Study coordinator: LIU, CHUANJU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases